Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab added to induction chemotherapy for older patients with AML or high-risk MDS
ISRCTN18332222Phase 2Completed
- Sponsor
- HOVON
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by HOVON. Primary endpoints: Incidence of dose-limiting toxicity and Complete remission rate. Started Feb 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN18332222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18332222.